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ABSTRACT
We have previously demonstrated that obese hyperandrogenic am-
enorrheic women are less likely to ovulate after clomiphene citrate
(CC) medication. The present study was designed to identify whether
additional endocrine screening characteristics, all potentially in-
volved in ovarian dysfunction in 182 normogonadotropic oligoamen-
orrheic infertile women, are associated with ovarian response, which
may improve overall prediction of CC-resistant anovulation. Stan-
dardized endocrine screening took place before initiation of CC med-
ication (50 mg/day; increasing doses up to 150 mg/day if required)
from cycle days 3–7. Screening included serum assays for fasting
insulin and glucose, insulin-like growth factor I (IGF-I), IGF-binding
protein-1 (IGFBP-1), IGFBP-3, free IGF-I, inhibin B, leptin, and vas-
cular endothelial growth factor. Forty-two women (22% of the total
group) did not ovulate at the end of follow-up (a total number of 325
cycles were analyzed). Fasting serum insulin, insulin/glucose ratio,
IGFBP-1, and leptin were all significantly different in univariate
analyses (P # 0.02), comparing CC responders vs. nonresponders.
Forward stepwise multivariate analyses in combination with factors
reported earlier for prediction of patients remaining anovulatory after
CC revealed a prediction model including 1) free androgen index
(FAI 5 testosterone/sex hormone-binding globulin ratio), 2) cycle his-
tory (oligomenorrhea or amenorrhea), 3) leptin level, and 4) mean
ovarian volume. These data suggest that decreased insulin sensitiv-
ity, hyperandrogenemia, and obesity, all associated with polycystic
ovary syndrome, are prominent factors involved in ovarian dysfunc-
tion, preventing these ovaries from responding to stimulation by
raised endogenous FSH levels due to CC medication. By using leptin
instead of body mass index or waist to hip ratio, the previous model
for prediction of patients remaining anovulatory after CC medication
could be slightly improved (area under the curve from 0.82–0.85).
This may indicate that leptin is more directly involved in ovarian
dysfunction in these patients. The capability of insulin and IGFBP-1
to predict patients who remain anovulatory after CC disappears when
FAI enters into the model due to a significant correlation between FAI
and these endocrine parameters. This suggests that markers for in-
sulin sensitivity (e.g. IGFBP-1 and insulin) are associated with ab-
normal ovarian function through its correlation with androgens,
whereas leptin is directly involved in ovarian dysfunction. (J Clin
Endocrinol Metab 85: 676–682, 2000)
CLOMIPHENE CITRATE (CC) is considered to be thefirst line strategy for ovulation induction in normogo-
nadotropic anovulatory infertility (WHO group 2) (1) since
its clinical introduction almost 4 decades ago (2). This syn-
thetic steroid, characterized by its mixed estrogenic and an-
tiestrogenic properties, is still extensively used. Approxi-
mately 75% of treated patients will ovulate after CC
medication (3–5), and once ovulation is achieved, cumulative
conception rates are 75% within six consecutive CC cycles (4,
6–8).
Polycystic ovary syndrome (PCOS), usually referred to as
chronic hyperandrogenic anovulation (9), is a common en-
docrine disorder and represents a significant proportion of
normogonadotropic anovulatory infertility (10). Etiological
factors involved in ovarian dysfunction in this heteroge-
neous patient group have not yet been fully elucidated. Var-
ious investigators reported on the prominent role of locally
produced growth factors, such as insulin-like growth factors
(IGFs) (11–13) or vascular endothelial growth factor (VEGF)
(14). Moreover, recent evidence suggests that decreased in-
sulin sensitivity plays an important role in initiating ovarian
dysfunction in these patients, possibly by stimulating thecal
cell androgen production (15, 16). A significant proportion of
patients with PCOS suffer from severe obesity (17, 18), and
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therefore, leptin, the hormone product of the obesity gene
(19), has been the focus of intense investigation (20–23). It has
been demonstrated that leptin can impair insulin action in
hepatocytes (20). Although leptin does not appear to play a
direct role in either hyperandrogenemia or hypersecretion of
LH (23), abnormalities in its signaling may be involved in
hypogonadotropic hypogonadism (24) and in certain cases of
PCOS (21). Finally, inhibin B, which has been shown to be
produced by healthy antral follicles under the control of FSH
in the early follicular phase of the normal menstrual cycle
(25), may serve as a marker for the severity of ovarian dys-
function in PCOS patients (26, 27).
We previously demonstrated that obese, hyperandro-
genic, amenorrheic women are less likely to respond to stim-
ulation by increasing endogenous FSH levels after CC com-
pared to normal weight, oligomenorrheic women presenting
with normal androgen concentrations (5). This approach
may have clinical implications in terms of health economics,
but may also provide information regarding factors involved
in ovarian dysfunction in these women. We now report on
the predictive power of additional endocrine screening of
factors potentially involved in ovarian abnormalities in this
patient population, including insulin sensitivity, the IGF sys-
tem, leptin, inhibin B, and VEGF.
Materials and Methods
Subjects and study protocol
Between February 1993 and January 1998, 182 women attending our
infertility unit presenting with 1) oligomenorrhea (bleeding intervals
between 35 days and 6 months) or amenorrhea (bleeding interval .6
months), 2) serum FSH levels within normal limits (1–10 IU/L) (1, 28)
and normal serum PRL and TSH levels, 3) spontaneous menses or
positive bleeding response to progestagen withdrawal, 4) body mass
index (BMI; weight divided by height squared) more than 18 kg/m2, and
5) age between 19–40 ys were included in the present study. Study
approval was obtained from the human subjects committee of the
Dijkzigt Hospital/Erasmus University, and informed consent was
obtained from all subjects.
Standardized initial clinical, sonographic, and endocrine screening
took place before initiation of induction of ovulation with CC medica-
tion, as described previously (5). Clinical screening included age, in-
fertility and cycle history, BMI, waist to hip ratio (WHR), previous
medication, and/or surgery. Transvaginal sonographic screening in-
cluded assessment of the ovarian stroma echogenicity (arbitrarily clas-
sified from one to three per ovary), ovarian volume (milliliters), and total
number of follicles (both ovaries), as described previously (10, 29). En-
docrine screening included serum assays for FSH, PRL, TSH, LH, es-
tradiol, androstenedione, testosterone, and sex hormone-binding glob-
ulin (SHBG), as described previously (5). In addition, serum was assayed
for fasting insulin and glucose, free and total IGF-I, IGF-binding pro-
tein-1 (IGFBP-1), IGFBP-3, inhibin B, leptin, and VEGF concentrations.
Fasting venous blood samples were taken on a random day between
0800–1000 h before initiation of therapy. Blood samples were centri-
fuged within 2 h after withdrawal and stored at 220 C until assayed.
Hormone assays
Serum insulin levels were measured by immunoradiometric assay
(IRMA; Biosource Technologies, Inc., Fleurus, Belgium), glucose lev-
els by the hexokinase method (Gluco-quant, Roche Molecular Bio-
chemicals, Mannheim, Germany) (30), and free IGF-I levels by a
two-site IRMA (Active, Diagnostic Systems Laboratories, Inc., Web-
ster, TX) direct assay. Serum was incubated in tubes and decanted,
and the tubes were washed according to the manufacturer’s instruc-
tions. Free IGF-I, bound to the tube, was detected by radiolabeled
antibody as described previously (31). Serum IGF-I levels were mea-
sured using a two-site IRMA (Active, Diagnostic Systems Laborato-
ries, Inc.), which includes an extraction step to separate the IGF-I from
its binding protein in serum. IGFBP-1 and IGFBP-3 levels were as-
sayed using a two-site IRMA (Active, Diagnostic Systems Laborato-
ries, Inc.) assay as described previously (31). The IGFBP-3 samples
were diluted 1:100 before assay. Dimeric inhibin B levels were mea-
sured using an immunoenzymometric assay (Serotec, Oxford, UK)
(32), leptin levels using a RIA (by means of reagents supplied by Linco
Research, Inc., St. Charles, MO) (33), and VEGF levels by enzyme
immunoassay (Cytokit Red EIA kits, Peninsula Laboratories, Inc.,
College Park, MD) (34). Midluteal serum progesterone (P) levels were
measured by RIA, as described previously (8). Intra- and interassay
coefficients of variation were less than 6.1% and 9.9% for insulin, less
than 1.0% and 1.9% for glucose, less than 10.3% and 10.7% for free
IGF-I, less than 3.4% and 8.2% for IGF-I, less than 5.2% and 6.0% for
IGFBP-1, less than 3.9% and 1.9% for IGFBP-3, less than 8% and 14%
for inhibin B, less than 3.6% and 4.6% for leptin, and less than 7.8%
and 12.2% for VEGF, respectively.
CC ovulation induction protocol
CC was administered at a daily dose of 50 mg (which was increased
to 100 and 150 mg in subsequent cycles in the case of absent ovarian
response) from cycle days 3–7 after initiation of a spontaneous or pro-
gestin-induced withdrawal bleeding, as described previously (5). Ovu-
lation after CC treatment was assessed by midluteal serum P levels
above 25 nmol/L combined with transvaginal sonographic monitoring
of follicle growth until visualization of a preovulatory follicle (mean
diameter, .18 mm) and subsequent disappearance or biphasic basal
body temperature charts, as indicated previously (5). If ovulation oc-
curred, the CC dose remained unaltered during subsequent cycles. The
duration of follow-up for all patients included in the study was at least
three treatment cycles. First ovulation after CC was used as the end
point. Responders were defined as patients who ovulated after CC,
independent of the dose administered. The number of treatment cycles
and the CC dose in which first ovulation occurred were recorded. Clo-
miphene-resistant anovulation (CRA) was defined as patients who did
not ovulate despite receiving maximum treatment doses of 150 mg/day.
Data analysis
P 5 0.05 was chosen as threshold level for statistical significance in
univariate analyses. For comparison of initial screening parameters of
CC responders and nonresponders, we used the Mann-Whitney U test
and Wilcoxon rank sum W test. The univariate relation with response
to CC was assessed using logistic regression analysis. The following
initial serum parameters were used in the multivariate analyses (for-
ward stepwise selection of variables, Pentry , 0.10): fasting serum insulin
and glucose, IGF-I, IGFBP-1, IGFBP-3, free IGF-I, inhibin B, leptin, and
VEGF in combination with parameters of the previous model for pre-
diction of patients remaining anovulatory after CC treatment, including
FAI, cycle history (oligomenorrhea vs. amenorrhea), BMI, and mean
ovarian volume (5). The area under the receiver operating characteristics
curve (AUC) was used to assess the discriminative ability of the tests,
as described previously (5). Data were analyzed using the commercially
available software package SPSS, Inc. (Chicago, IL).
Results
From the total number of 182 patients fulfilling the in/
exclusion criteria and treated with CC medication, 131 (72%)
suffered from primary infertility, 43 (24%) from amenorrhea,
and the remaining 139 (76%) had oligomenorrhea. Eighty-
two (45%) women were obese (BMI, $26), 113 (62%) patients
presented with an elevated FAI ($4.0), and 67 (37%) patients
presented with hyperandrogenemia (testosterone, $3.2
nmol/L; and/or androstenedione, $16.3 nmol/L) (10, 35). In
134 patients (74%) polycystic ovaries (mean ovarian volume,
$10.8 mL; and/or mean follicle number per ovary, $10) (10,
29) were diagnosed. Finally, 93 patients (51%) presented with
elevated serum LH levels ($7.0 IU/L) (10, 35). From the total
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group of patients, 40 (22%) women remained anovulatory
despite the maximum CC dose. A total number of 325 CC
cycles were analyzed (205 ovulatory and 120 anovulatory
cycles).
Endocrine screening characteristics of the overall study
group and separately for patients who did or did not ovulate
after CC medication are presented in Table 1. Fasting insulin
level, insulin/glucose ratio, and serum leptin levels were
significantly higher and IGFBP-1 levels significantly lower in
CRA patients. P values after univariate analysis with logistic
regression analyses, odds ratio, 95% confidence interval, and
the receiver operating characteristics AUC of additional ini-
tial endocrine screening parameters are depicted in Table 2.
Again, serum insulin, insulin/glucose ratio, IGFBP-1, and
leptin levels were significantly different between patients
who did vs. those who did not ovulate after CC treatment.
Results of multivariate analyses for prediction of patients
remaining anovulatory after CC induction of ovulation are
depicted in Table 3. Using a forward stepwise selection pro-
cedure, various significant predictors during univariate anal-
ysis (such as insulin, IGFBP-1, and BMI) disappear, and four
variables were eventually selected: 1) FAI, 2) cycle history
(oligomenorrhea vs. amenorrhea), 3) leptin, and 4) mean
ovarian volume. The association of FAI, leptin, and insulin
with other endocrine and clinical features was analyzed in
more detail. Correlations between FAI and BMI, leptin, in-
sulin, and IGFBP-1 are depicted in Fig. 1. Correlations be-
tween initial serum leptin levels and BMI, WHR, and insulin
are shown in Fig. 2. Correlations between initial serum in-
sulin levels and BMI, SHBG, and IGFBP-1 are shown in Fig.
3. For all figures, individual correlations are shown sepa-
rately for CC responders and nonresponders. With the ex-
ception of leptin, correlations between all other factors de-
picted in the figures were significantly stronger in CC
nonresponders than in responders (data not shown).
Discussion
The present prospective follow-up study was designed to
evaluate whether initial screening of insulin sensitivity, the
IGF system, leptin, inhibin B, or VEGF could predict the
ovarian response to CC medication in normogonadotropic
oligomenorrheic infertile women. We recently reported (5)
that obese, hyperandrogenic, amenorrheic women, a com-
plex of signs and symptoms frequently referred to as PCOS
(9), are more likely to remain anovulatory after CC medica-
tion. As a first step we focused on screening of the most
pertinent clinical, endocrine, and sonographic characteristics
of these patients (5). Further endocrine parameters poten-
tially related to ovarian dysfunction in these women are the
focus of the present study. Decreased insulin sensitivity/
hyperinsulinemia or augmented free IGF-I may be involved
in the pathophysiology of this heterogeneous syndrome by
directly stimulating thecal cell androgen production (13, 15,
16). Serum leptin levels were also assessed in these patients,
as it has been suggested recently that this is a reliable en-
docrine marker for obesity. Abnormalities in its signaling
pathway may be involved in hypogonadotropic hypogonad-
ism (24) and eventually in certain cases of PCOS (21, 22). In
addition, leptin may directly modulate insulin activity in
obese individuals (20). Inhibin B is produced by healthy early
antral follicles under the control of FSH in the early follicular
phase of the menstrual cycle (25) and may therefore be used
as a marker for the severity of ovarian abnormalities (i.e. the
sensitivity to FSH and assessment of the number of healthy,
rather than atretic, follicles in polycystic ovaries) and the
TABLE 1. Endocrine findings (mean 6 SD) upon initial screening of 182 normogonadotropic oligoamenorrheic infertile womena and
separately for patients who did (CC responders) or did not (CRA) ovulate after CC induction of ovulation
Overall group
(n 5 182)
CC responder
(n 5 142; 78%)
CRA
(n 5 40; 22%) P value
b
Insulin (mU/L) 14.7 6 10.4 13.6 6 9.5 19.0 6 13.0 0.009
Glucose (mmol/L) 4.3 6 1.6 4.2 6 1.0 4.8 6 2.9 —c
Insulin/glucose ratio 3.6 6 2.5 3.4 6 2.3 4.4 6 3.0 0.05
Inhibin B (ng/L) 153 6 102 156 6 103 149 6 99 —
IGF-I (ng/mL) 237 6 97 242 6 99 218 6 83 —
Free IGF-I (ng/mL) 2.8 6 1.7 2.8 6 1.6 3.0 6 2.0 —
IGFBP-1 (ng/mL) 24.2 6 18.1 26.4 6 18.5 16.7 6 14.5 0.001
IGFBP-3 (ng/mL) 3297 6 693 3320 6 714 3240 6 622 —
Leptin (ng/mL) 21.6 6 17 19.3 6 15 30.4 6 20 0.003
VEGF (ng/mL) 4.8 6 2.9 4.9 6 2.9 4.3 6 3.1 —
a Remaining characteristics: age, 28 6 4.5 yr; BMI, 26.5 6 6 kg/m2; T, 2.4 6 0.9 nmol/L; FAI, 6.2 6 4.2; LH, 7.9 6 4.4 IU/L; FSH, 4.5 6 4.6
IU/L; E2, 258 6 174 pmol/L; and mean ovarian volume, 9.8 6 4.2 mL.
b Comparison of CC responders vs. CRA (by Mann-Whitney U test).
c Not significant.
TABLE 2. Univariate logistic regression analyses, odds ratio, 95%
confidence interval, and area under the ROC curve of endocrine
screening parameters in 182 normogonadotropic oligoamenorrheic
infertile women for the prediction of patients remaining
anovulatory after CC induction of ovulation
Univariate analyses Odds ratio (95% CIa) Pb value AUCc
Insulin (mU/L) 1.05 (1.01–1.08) 0.005 0.64
Glucose (mmol/L) 1.21 (0.97–1.50) 0.07 0.51
Insulin/glucose ratio 1.16 (1.01–1.32) 0.03 0.61
Inhibin B (ng/L) 0.99 (0.99–1.00) 0.5 0.53
IGF-I (ng/mL) 0.99 (0.99–1.00) 0.2 0.56
Free IGF-I (ng/mL) 1.06 (0.86–1.30) 0.3 0.51
IGFBP-1 (ng/mL) 0.96 (0.93–0.98) 0.01 0.67
IGFBP-3 (ng/mL) 0.99 (0.99–1.00) 0.6 0.54
Leptin (ng/mL) 1.03 (1.01–1.06) 0.0003 0.70
VEGF (ng/mL) 0.92 (0.79–1.07) 0.4 0.58
a Confidence interval.
b Univariate logistic regression analyses with likelihood ratio test
(Bold 5 P , 0.05).
c Area under the ROC curve. (Bold 5 P , 0.05).
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likelihood of ovaries to respond to ovulation induction (27).
Finally, VEGF levels were assessed in these patients, as recent
reports suggest that this protein may serve as a marker for
changes in ovarian stroma of PCOS patients (14, 34).
The present study demonstrates that serum insulin, insu-
lin/glucose ratio, and leptin levels are significantly higher
and, in contrast, IGFBP-1 levels are lower in patients who
remain anovulatory after CC. When a multivariate analysis
for the prediction of CRA is applied, the capacity of serum
insulin, insulin/glucose ratio, and IGFBP-1 levels to predict
CRA is eliminated when FAI enters into the model due to a
strong correlation between these parameters and FAI. In
contrast, leptin levels enter into the model in the third step.
These results can be interpreted as follows. Insulin is signif-
icantly higher in CRA patients. An association between de-
creased insulin sensitivity and hyperandrogenism is well
known (36, 37). Signal transduction via the insulin receptor
has been demonstrated to be frequently abnormal in PCOS
(38). Moreover, IGF-I as well as insulin have been shown to
augment LH-induced androgen biosynthesis by cultured
thecal cells (38). As insulin binds to the structurally similar
type 1 IGF receptor, it has been postulated that high levels
of circulating insulin stimulate thecal cell androgen produc-
tion through the type 1 IGF receptors (36, 37). However, this
seems to be the case only in extreme hyperinsulinism, such
as in patients suffering from leprechaunism. Moreover, in-
sulin and BMI are the major determining factors of circulat-
ing IGFBP-1 levels in both normoovulatory obese and PCOS
women. Insulin reduces circulating SHBG (39–41) and
IGFBP-1 levels by inhibiting the production of these proteins
in the liver (39, 41). Apparently, the liver is excluded from
reduced sensitivity for insulin stimulation. Accordingly, it
has been proposed that IGFBP-1 levels may be used as a
simple marker for insulin resistance (48). Several researchers
indicated lower circulating levels of IGFBP-1 (39, 50, 51), but
not IGFBP-3 (51), in PCOS patients compared to normal
cycling women (33–35, 48). Moreover, insulin may also in-
hibit IGFBP-1 production in ovarian granulosa cells, by act-
ing through its own receptor (37). Circulating serum SHBG
concentrations are significantly reduced in obese normoovu-
latory women (39) and in oligoamenorrheic CC-resistant in-
fertile patients (5). Moreover, an increase in circulating serum
SHBG concentration has been reported in ovulatory patients
after CC medication (42) as well as in women with PCOS
using insulin-sensitizing agents (43, 44). An insufficient or
absent rise in circulating serum SHBG concentrations (with
FIG. 1. Correlations between FAI (testosterone 3 100/SHBG) and
BMI, serum leptin, insulin, and IGFBP-1 in 182 normogonadotropic
oligomenorrheic infertile patients using a scatter plot. Open circles
represent patients who ovulated after CC treatment, and closed cir-
cles represent CC nonresponders.
TABLE 3. Forward stepwise multivariate analyses of parameters of the prediction model plus additional endocrine screening for
prediction of normogonadotropic oligoamenorrheic patients remaining anovulatory during clomiphene citrate induction of ovulation
Analyses: Univariatea Multivariate
Steps: 0 1 2 3 4b
Screening parameters
a) Prediction modelc
FAId ,0.0001 In model In model In model In model
BMI (kg/m2) 0.0003 0.03 0.04 0.46 0.46
Mean ovarian vol (mL) 0.007 0.12 0.13 0.06 In model
Cycle historye 0.0003 0.0001 In model In model In model
b) Additional endocrine parameters
f
Insulin (mU/L) 0.005 0.32 0.45 0.93 0.98
Insulin/glucose ratio 0.03 0.66 0.79 0.64 0.56
IGFBP-1 (ng/mL) 0.01 0.82 0.71 0.74 0.64
Leptin (ng/mL) 0.0003 0.01 0.009 In model In model
a Step 0, Comparison of CC responders vs. CRA (univariate logistic regression analyses).
b Final model, Area under the ROC curve, 0.85; multivariate odds ratio (95% CI) of FAI, 1.19 (1.07–1.32); of cycle history, 0.16 (0.05–0.42);
of mean ovarian volume, 1.11 (0.99–1.24); and of leptin, 1.04 (1.01–1.06). This means that, for instance, a 1-U increase in a given patient’s serum
leptin level gives her a 4% higher probability to be a CRA.
c As published previously (5).
d FAI 5 T 3 100/SHBG.
e Amenorrhea vs. oligomenorrhea.
f Only parameters that are significantly different (see Table 2) are included.
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resulting high free androgen levels) after CC medication
could be held responsible for CC unresponsiveness.
In the present study total and free IGF-I and IGFBP-3 levels
are comparable between CC responders and nonresponders.
No differences in IGFBP-3 levels were previously noted in
follicular fluid from PCOS ovaries compared with androgen-
dominant and estrogen-dominant follicles from normo-
ovulatory women (45, 46). In contrast, IGFBP-1 levels are
significantly lower in patients remaining anovulatory after
CC medication. As a consequence of decreased hepatic pro-
duction of serum IGFBP-1 levels, a greater proportion of
IGF-I is biologically active (47). Taking into account that
serum IGFBP-1 levels increase (48) and IGF-I levels decrease
(42) in oligoamenorrheic women after CC medication, it may
be suggested that an insufficient rise in serum IGFBP-1 levels
after CC medication is involved in the follicle growth arrest
in these patients. No difference could be observed in pre-
treatment free IGF-I levels comparing responders vs. CRA
patients. Overall, FAI is the most significant factor to predict
ovarian response. It appears that the prediction of insulin
and IGFBP-1 completely depends on its association with FAI,
in line with recent compelling molecular evidence for intrin-
sic abnormalities in the androgen synthesis pathway in
PCOS thecal cells (49). It is likely that decreased IGFBP-1 is
an excellent marker of hyperinsulinemia and that it does not
affect the endocrine IGF system’s effect on follicle growth.
The present study demonstrates a significant correlation
between leptin levels and BMI and WHR, which is in agree-
ment with previous reports (21–23). Serum leptin levels were
significantly higher in CC nonresponders and enter into the
model (instead of BMI) in multivariate analyses to predict
CRA. The AUC of the previously developed prediction
model (including FAI, BMI, cycle history, and mean ovarian
volume) of 0.82 could be slightly improved to 0.85 by the
inclusion of leptin rather than BMI. Due to the limited im-
provement of the AUC and the fact that information such as
weight and height of the patient is easy to collect, one may
prefer to use BMI to predict the probability of CRA in clinical
FIG. 2. Correlations between serum leptin and BMI, WHR, and
serum insulin in 182 normogonadotropic oligomenorrheic infertile
patients using a scatter plot. Open circles represent patients who
ovulated after CC treatment, and closed circles represent CC non-
responders.
FIG. 3. Correlations between serum insulin and BMI, SHBG, and
serum IGFBP-1 in 182 normogonadotropic oligomenorrheic infertile
patients using a scatter plot. Open circles represent patients who
ovulated after CC treatment, and closed circles represent CC nonre-
sponders.
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practice. Clearly, the end point for clinical practice should be
pregnancy rather than ovulation. It has been demonstrated
that leptin can directly impair insulin action in hepatocytes
(20). In addition, leptin directly inhibits IGF-I augmentation
of FSH-stimulated estradiol production (50) as well as LH-
stimulated androgen synthesis in vitro (50). In vivo observa-
tions, however, would argue against a negative correlation
between obesity/elevated leptin levels and androgens. High
leptin levels could interfere with the ability of the dominant
follicle to produce estradiol, both by inhibiting the produc-
tion of androgen substrate and by decreasing the aromatiz-
ing capacity of granulosa cells (51). Moreover, changes in
estradiol and P during the human menstrual cycle may par-
ticipate in the control of leptin production (52). Caloric re-
striction, exercise, and weight-reducing diets may reduce
leptin levels (53); result in normalization of insulin sensitiv-
ity, gonadotropins, and androgen metabolism (54); and lead
to spontaneous ovulatory cycles in up to 50% of women (55).
Initial serum inhibin B as well as serum VEGF levels were
similar comparing CC responders and nonresponders. These
endocrine parameters had no predictive value for ovarian
response to CC medication. The results of this study suggest
that circulating inhibin B does not correspond to the number
of healthy follicles present in polycystic ovaries, character-
ized by follicle maturation arrest and atresia of a proportion
of follicles. This is in contrast with the conclusion of a recent
report focusing on a relatively small group of patients (27).
Recent observations suggest that increased intraovarian con-
centrations of VEGF may be related to increased stroma
echogenicity and vascularity and increased secretion and
pulsatility of LH (34). We have not been able to confirm that
VEGF levels may represent the magnitude of ovarian dys-
function in these women.
The impact of markers for insulin sensitivity, the IGF sys-
tem, leptin, inhibin B, and VEGF on the prediction of con-
ception after ovulatory CC cycles has also been analyzed.
None of these parameters predicts the probability of con-
ceiving in women who ovulated after CC treatment (data not
shown). This stresses again the concept previously put for-
ward (8) that follicle growth and oocyte quality are differ-
entially regulated.
In conclusion, the present longitudinal follow-up study
suggests that FAI, as a marker for the severity of hyperan-
drogenemia, is the most significant endocrine marker of
ovarian dysfunction and for the prediction of ovarian re-
sponse after CC medication. Initial serum leptin insulin, and
IGFBP-1 levels are factors in univariate analyses predicting
patients who will remain anovulatory after CC. The capa-
bility of serum insulin and IGFBP-1 to predict CRA disap-
pears when FAI enters into the model due to a significant
correlation between FAI and these endocrine parameters.
Finally, leptin is a better marker to predict ovarian response
to CC medication compared to BMI. For the assessment of
markers useful for clinical screening in patients, the present
observations predicting ovarian response should be com-
bined with factors predicting pregnancies in ovulatory CC
women. Moreover, the question arises of whether factors
involved in ovarian response or conception after CC medi-
cation may also predict individual responses to exogenous
gonadotropins in patients who fail to ovulate or conceive
after CC.
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